About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

By: via Business Wire

Silexion Therapeutics approaches a potential key milestone with upcoming orthotopic pancreatic cancer model data, which, if positive, could validate systemic efficacy against metastatic disease for the first time. Reportedly, Maxim Group maintains a $9 price target and strong buy rating, citing the company's growing clinical trajectory and RNAi platform validation. With a data readout expected this month, this could be a major catalyst for the company, as interest for innovative KRAS-targeting therapies continues to rise

PESG Research releases a new market update on Silexion Therapeutics (NASDAQ: SLXN). Silexion recently announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models, a critical milestone that could continue to position its next-generation RNAi therapy at the forefront of KRAS-driven cancer treatment. With data analysis now underway and initial results expected in the coming weeks, according to the company’s latest announcement, anticipation seems high for what could be a pivotal breakthrough, if indeed the data is positive.

A Potential Step Toward Transforming Pancreatic Cancer Treatment

Silexion’s latest study could mark an important advancement in validating systemic administration of SIL-204. The study specifically assessed the therapy’s ability to reduce primary tumor growth and inhibit metastatic spread in clinically relevant orthotopic pancreatic cancer models—providing a more accurate representation of human disease progression than traditional subcutaneous xenograft models.

Silexion’s work with SIL-204 has already demonstrated compelling preclinical efficacy, including a 50% reduction in tumor growth and complete necrosis in half of treated tumors in previous systemic administration studies. Moreover, SIL-204 has shown sustained therapeutic levels for over 56 days from a single dose—an unprecedented achievement in RNAi-based therapies for KRAS-driven cancers.

Why This Matters: A Potential First for Metastatic Pancreatic Cancer

KRAS-driven cancers remain among the most aggressive and difficult-to-treat malignancies, particularly in pancreatic cancer, where over 90% of tumors harbor KRAS mutations. While other companies have attempted to target KRAS with small molecule inhibitors, Silexion’s RNAi-based approach aims to silence multiple key KRAS mutations, including G12D, G12V, G12R, Q61H, and G13D—offering a broader and potentially more effective therapeutic strategy.

The ability to target both primary and metastatic pancreatic cancer via systemic administration would represent a major breakthrough, as Silexion has not previously demonstrated this effect in metastatic models. If the orthotopic model results show significant impact on metastases, this could mark a critical validation step, potentially differentiating SIL-204 from existing KRAS-targeting approaches and opening the door to expanded clinical applications.

The industry seems to be closely watching Silexion’s progress in light of the recent wave of multi-billion-dollar acquisitions in precision oncology. With major players like Pfizer acquiring Seagen for $43 billion and AbbVie purchasing Immunogen for $10.1 billion, the demand for novel cancer therapies seems to have increased in recent years. According to news reports, Maxim Group recently reaffirmed its strong buy rating on SLXN with a $9 price target, citing the company’s strong clinical trajectory and the ongoing validation of its RNAi platform.

Upcoming Data Readout: A Potential Critical Catalyst

Silexion’s announcement that initial results from the orthotopic model study will be released in March 2025 has sparked significant interest. If the data is positive, it could provide further confirmation of SIL-204’s ability to target both primary and metastatic pancreatic cancer, marking the first time the company demonstrates systemic efficacy against metastatic disease.

If the upcoming results align with previous systemic administration findings and show significant impact on metastases, SIL-204 could emerge as a leading next-generation RNAi therapy for KRAS-driven cancers—potentially, in the future, reshaping the treatment paradigm for one of the deadliest malignancies.

Silexion Therapeutics has continued to execute on its strategy, pushing the boundaries of RNAi therapeutics for one of the most aggressive cancers. With data from the orthotopic pancreatic cancer study expected in March, many will likely be watching closely. If the upcoming results are positive and demonstrate impact on metastases, they could serve as a major catalyst for the company, potentially redefining its role in the precision oncology landscape.

Given the strong track record of preclinical success, increasing interest, and a competitive landscape ripe for M&A activity, Silexion Therapeutics is undoubtedly a company to watch in 2025.

Recent News from Silexion

Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This alert is published by Market News Alerts, a brand which is part of the Wall Street Wire™ network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This distribution contains paid promotional content related to Silexion Therapeutics and was produced as part of their paid subscription to Wall Street Wire. This alert has not been reviewed or approved by Silexion Therapeutics prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms.

Contacts

More News

View More
3 Healthcare Stocks Using AI to Drive Growth
Via MarketBeat
Topics Artificial Intelligence
Tickers BSX HIMS TEM
Get Exposure to Millennials' Purchasing Power With This ETF
Via MarketBeat
Topics ETFs
Tickers AAPL DASH DIS GOOGL META MILN
Why a $4.5 Billion Smart Debt Move Is Fueling Dell’s AI Ambitions
Via MarketBeat
Topics Artificial Intelligence
Tickers DELL
Beam Global Gets Buy Rating With 101% Upside Potential
Via MarketBeat
Topics Intellectual Property
Tickers BEEM
These 3 Crypto Stocks Could Get a Bump as Dollar Trust Weakens
Via MarketBeat
Topics ETFs Economy World Trade
Tickers BITF COIN HOOD
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.